Alnylam Pharmaceuticals, Inc. (ALNY)
336.19
-3.18
(-0.94%)
USD |
NASDAQ |
Feb 20, 16:00
337.00
+0.81
(+0.24%)
After-Hours: 20:00
Alnylam Pharmaceuticals SG&A Expense (Quarterly) : 325.37M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Insmed, Inc. | 212.48M |
| Biogen, Inc. | 682.50M |
| Pfizer Inc. | 4.162B |
| Eli Lilly & Co. | 3.132B |
| AbbVie, Inc. | 3.895B |